DESCRIPTION (provided by applicant): Quorum sensing is a cell-to-cell communication system that permits members of a bacterial population to coordinate their behavior dependent on cell density. The mediators of quorum sensing are small, diffusible pheromones or autoinducers that signal gene expression programs at a sufficient bacterial density. The list of bacterial pathogens that use this method of communication to regulate host colonization and virulence is expanding and includes some of the most common pathogens of humans. We hypothesized that several mammalian effectors contribute to innate immunity by inhibiting pathogenic bacterial communication via "quorum quenching." In preliminary data we show that phagocyte-derived reactive oxygen and nitrogen intermediates (ROI and RNI) target a virulence-inducing peptide of the medically important human pathogen Staphylococcus aureus as an innate defense mechanism of the host. In addition, enzymes in blood and epithelial cells that cleave lactone bonds that are present in these autoinducers could inhibit quorum sensing-dependent virulence. To test this hypothesis, we will pursue the following specific aims: 1) To determine the contribution of phagocyte-derived ROI and RNI to host defense against infection with quorum sensing-sufficient and -deficient strains of S. aureus and S. epidermidis and the ability of ROI and RNI to functionally inactivate the virulence pheromones secreted by these pathogens; 2) To determine the ROI- and RNI-mediated modifications of these virulence pheromones by mass spectrometry in vitro and their biologic significance in vivo; and 3) To determine if non-phagocyte innate effectors inhibit quorum sensing-dependent virulence. These will include the paraoxonase enzyme family (thiolactonases) and the epithelial cell-expressed Nox/Duox enzymes (oxidases and peroxidases). Understanding the contribution of these innate effectors to quorum quenching and how pathogens avoid it could augment drug design that targets virulence pheromones for inactivation.
National Institute of Allergy and Infectious Diseases
CFDA Code
855
DUNS Number
868853094
UEI
F6XLTRUQJEN4
Project Start Date
01-April-2005
Project End Date
31-December-2009
Budget Start Date
01-January-2007
Budget End Date
31-December-2007
Project Funding Information for 2007
Total Funding
$355,568
Direct Costs
$237,045
Indirect Costs
$118,523
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Allergy and Infectious Diseases
$355,568
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01AI064926-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01AI064926-03
Patents
No Patents information available for 5R01AI064926-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01AI064926-03
Clinical Studies
No Clinical Studies information available for 5R01AI064926-03
News and More
Related News Releases
No news release information available for 5R01AI064926-03
History
No Historical information available for 5R01AI064926-03
Similar Projects
No Similar Projects information available for 5R01AI064926-03